Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Health Tech·Omada Health

Omada Health swings to a profit and lifts 2026 forecast as members reach 1.1 million

The virtual chronic care company's third-quarter revenue rose 34% to $91.3 million, it earned $6.6 million, and it raised its full-year adjusted EBITDA forecast to $32 million to $34 million.

From Omada Health's third-quarter earnings release, filed with the SEC Nov. 5, 2026
Connected devices shown in Omada Health's media kit, including a scale, a blood pressure monitor and a blood glucose meter.
Connected devices shown in Omada Health's media kit, including a scale, a blood pressure monitor and a blood glucose meter.Courtesy of Omada Health

A year ago, Omada Health lost $3.2 million in the third quarter. This year it earned $6.6 million.

The virtual chronic care company said Nov. 5 that third-quarter revenue rose 34% to $91.3 million from $68.0 million and that total members reached 1.1 million, up 36% from a year earlier. It raised its full-year forecasts for both revenue and adjusted EBITDA.

Why it matters: Omada raised its adjusted EBITDA outlook far more, proportionally, than its revenue outlook. The midpoint of its adjusted EBITDA forecast rose about 38% to $33 million, while the revenue midpoint rose about 2% to $345 million, and gross margin reached 76%, up from 66% a year earlier.

Omada's report came three days after Hinge Health, which also runs a musculoskeletal care program, said its revenue rose 52% and raised its own outlook.

Members and tenure

Enrollment growth was led by its diabetes and hypertension programs, Omada said. It counts as a member anyone enrolled in one of its programs who has produced a billing event within the past 12 months.

Revenue per member over the trailing 12 months grew about 5% to $294. Average member tenure rose 10% to roughly two years and four months, which the company said amounts to about two and a half more months in a program.

Sean Duffy, co-founder and chief executive, called it the company's "strongest quarter yet" in the release.

Profit and cash

Adjusted EBITDA, as the company defines it, was $12.4 million, up from $2.4 million, for a margin of 14% compared with 4%. Omada ended the quarter with $243 million in cash and cash equivalents.

For the first nine months of 2026, revenue was $257.2 million, up from $184.4 million, and net income was $8.9 million, compared with a net loss of $17.9 million. Adjusted EBITDA for the nine months was $24.1 million, versus a loss of $2.0 million on that basis a year earlier.

The business

Omada describes itself as a virtual between-visit care provider for chronic conditions such as obesity, diabetes, hypertension, cholesterol and musculoskeletal conditions. Its model combines care teams, connected devices and software, including support for patients on GLP-1 medications, according to the company. Omada says it has served more than 2 million members since launch through more than 2,000 employers, health plans, pharmacy benefit managers and health systems.

What to watch

Omada now expects 2026 revenue of $344 million to $346 million, up from $334 million to $340 million, which it said would be about 33% growth at the midpoint. It expects adjusted EBITDA of $32 million to $34 million, up from $21 million to $27 million, or about 5.5 times its 2025 level at the midpoint.

Those ranges, set against the nine-month results, imply fourth-quarter revenue of about $86.8 million to $88.8 million and adjusted EBITDA of about $7.9 million to $9.9 million, both below third-quarter levels. The release did not explain the implied step down. Omada did not provide a net income forecast, citing the variability of items excluded from adjusted EBITDA.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Health Tech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.